If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code J3590. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
As of J, a permanent J-code is available for the IV formulation of COSENTYX (secukinumab). HCPs should contact third-party health plans for
Secukinumab (Cosentyx) for subcutaneous (SC) administration was approved by the U.S. Added HCPCS code. J3247 and deleted code C9166.
If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code, J3590. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
Manufacturer: Cosentyx HCPCS: C9166 Effective Date: HCPCS Code Descriptor: Cosentyx NDCs: Primary Type: Generic/Specialty Status: Package Type:.
Cosentyx is a medication manufactured by Novartis Pharmaceuticals Corporation and aligned to the J Code: J3247. Cosentyx is administered via the Intravenous route of administration.
For infusion dates of service on or after J, use J-code J3247 when submitting claims for the IV formulation of COSENTYX. For dates of service prior
COSENTYX IV (secukinumab) COSENTYX IV (secukinumab). MAPD Prior do not have a J code assigned by the FDA. New drugs may take between
For infusion dates of service on or after J, use J-code J3247 when submitting claims for the IV formulation of COSENTYX. The permanent J-code enables providers and office staff to code with specificity, for claims processing purposes, after COSENTYX is given to a patient.1,2
R.